Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25075448 | 0.98 | HRH3 (0.38) | HRH3 | |
| SCHEMBL26497168 | 0.84 | HRH3 (0.40) | HRH3TLR7 | |
| SCHEMBL16021413 | 0.82 | HRH3 (0.44) | HRH3TLR7 | |
| SCHEMBL25725586 | 0.81 | PIK3CD (0.37) | HRH3 | |
| SCHEMBL102140 | 0.81 | HRH3 (0.45) | HRH3 | |
| SCHEMBL26501021 | 0.80 | PIK3CD (0.36) | HRH3 | |
| SCHEMBL25075199 | 0.80 | HRH3 (0.35) | HRH3 | |
| SCHEMBL17995585 | 0.78 | HRH3 (0.43) | HRH3TLR7 | |
| SCHEMBL18537061 | 0.78 | CYP1A2 (0.39) | — | |
| SCHEMBL13405197 | 0.78 | HRH3 (0.43) | HRH3TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2023023537-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. (US) | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | HRH3 3222/4885TLR7 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.